Drug Trial Radar · NCT00605683
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Last checked: Nov 19, 2026Latest source record: Oct 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
679
Actual
Start
Nov 2007
Primary completion
Jan 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Newron Pharmaceuticals SPAIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations.
Conditions
- Idiopathic Parkinson's Disease
Interventions
Safinamide (as add-on therapy)Drug
Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
Safinamide (as add-on therapy)Drug
Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Safinamide (as add-on therapy)Drug
Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the changes from baseline to W24 in motor symptoms (UPDRS Section III).Time frame: 24 weeks
Locations
125 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Neurological Institute
Phoenix, Arizona
Pacific Neuroscience Medical Group
Oxnard, California
San Francisco Clinical Research Center
San Francisco, California
Parkinson's Institute
Sunnyvale, California
Institute for Neurodegenerative Disorders
New Haven, Connecticut
Parkinson's Disease and Movement Disorder Center
Boca Raton, Florida
Neurologic Consultants P.A.
Fort Lauderdale, Florida
University Of Florida
Gainesville, Florida
Parkinson's Disease Treatment Center of SW Florida
Port Charlotte, Florida
Neurology Clinical Research Inc.
Sunrise, Florida
University Of South Florida Medical Center
Tampa, Florida
Emory University
Atlanta, Georgia
Medical College of Georgia
Augusta, Georgia
Columbus Research Institute
Columbus, Georgia
Northwestern University PD and Movement Disorders Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
University of Maryland Medical Center
Baltimore, Maryland
Boston University School of Medicine
Boston, Massachusetts
Parkinson's Disease and Movement Disorders Center of Albany
Albany, New York
North Shore Medical Center
Manhasset, New York
Columbia University Medical Center
New York, New York
New York University
New York, New York
The Neurological Institute
Charlotte, North Carolina
Duke University Health Systems
Druham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Neurology Specialists
Dayton, Ohio
Oregon Health & Science University
Portland, Oregon
Lankenau Hospital
Wynnewood, Pennsylvania
Butler Hospital
Providence, Rhode Island
Baylor College of Medicine
Houston, Texas
Hospital Español
Buenos Aires, Argentina
Instituto de Neurociencias Buenos Aires S.A.
Buenos Aires, Argentina
Clinica IMECO
Capital Federal, Argentina
Hospital Italiano de Buenos Aires
Capital Federal, Argentina
Instituto de Investigaciones Neurológicas Raul Carrea FLENI
Capital Federal, Argentina
Instituto Frenopatico S.A.
Capital Federal, Argentina
Instituto Argentino de Investigacion Neurologica SRL
Ciudad Autonoma de, Argentina
Instituto Medico Congreso
Ciudad Autonoma de Bs. As., Argentina
Instituto INEBA
Ciudad Autónoma de Bs. As., Argentina
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.